U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07203846) titled 'Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor' on Sept. 25.
Brief Summary: The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.
Study Start Date: Jan. 01, 2026
Study Type: INTERVENTIONAL
Condition:
ACS - Acute Coronary Syndrome
Ticagrelor
Microbiota
Platelet Aggregation
Myocardial Infarction (MI)
Blood Platelets
Drug Eff...